News
The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...
Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.
Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.
BEIJING, China & NANJING, China, China I June 04, 2025 I Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results